
Pharmacally
Fibrosis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Fibrosis
Clinical TrialsEndeavor’s Taladegib Improves Lung Function in Phase 2b IPF TrialEndeavor BioMedicines’ taladegib met the primary endpoint in the Phase 2b WHISTLE-PF trial, significantly improving ppFVC versus placebo in patients with idiopathic pulmonary fibrosis.Fact-Checked
Mergers & AcquisitionsOno and Mediar Partner to Develop Novel Antibody Therapies for FibrosisOno Pharmaceutical and Mediar Therapeutics have entered a discovery collaboration to develop novel antibody therapeutics targeting myofibroblasts for fibro-inflammatory diseases.Fact-Checked
Clinical TrialsAltimmune Reports Strong Fibrosis Improvements With Pemvidutide in MASHAltimmune presented new data from the Phase 2b IMPACT trial at the EASL Congress 2026, highlighting pemvidutide’s ability to improve overlapping non-invasive markers of MASH activity and fibrosis…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.